Y
Yimin Li
Publications - 20
Citations - 1423
Yimin Li is an academic researcher. The author has contributed to research in topics: Virus & Vaccination. The author has an hindex of 9, co-authored 17 publications receiving 1165 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
Fengcai Zhu,Jun Zhang,Xuefeng Zhang,Cheng Zhou,Zhong-Ze Wang,Shoujie Huang,Hua Wang,Chang-Lin Yang,Han-Min Jiang,Jia-Ping Cai,Yi-Jun Wang,Xing Ai,Yuemei Hu,Quan Tang,Xin Yao,Qiang Yan,Yangling Xian,Ting Wu,Yimin Li,Ji Miao,Mun-Hon Ng,James Wai-Kuo Shih,Ningshao Xia +22 more
TL;DR: HEV 239 is well tolerated and effective in the prevention of hepatitis E in the general population in China, including both men and women age 16-65 years and no vaccination-related serious adverse event was noted.
Journal ArticleDOI
Long-Term Efficacy of a Hepatitis E Vaccine
Jun Zhang,Xuefeng Zhang,Shoujie Huang,Ting Wu,Yuemei Hu,Zhong-Ze Wang,Hua Wang,Han-Min Jiang,Yi-Jun Wang,Qiang Yan,Meng Guo,Xiao-Hui Liu,Jingxin Li,Chang-Lin Yang,Quan Tang,Ren-Jie Jiang,Huirong Pan,Yimin Li,J. Wai-Kuo Shih,Mun-Hon Ng,Fengcai Zhu,Ningshao Xia +21 more
TL;DR: Immunization with this hepatitis E vaccine induced antibodies against HEV and provided protection against hepatitis E for up to 4.5 years, with a vaccine efficacy of 86.8% in the modified intention-to-treat analysis.
Long-Term Efficacy of a Hepatitis E Vaccine ; 戊型肝炎疫苗的长期保护效果
Jun Zhang,夏宁邵,Xuefeng Zhang,Shoujie Huang,Ting Wu,Yuemei Hu,Zhong-Ze Wang,Hua Wang,Han-Min Jiang,Yi-Jun Wang,Qiang Yan,Meng Guo,Xiao-Hui Liu,Jingxin Li,Chang-Lin Yang,Quan Tang,Ren-Jie Jiang,Huirong Pan,Yimin Li,J. Wai Kuo Shih,J. Wai-Kuo Shih,Mun-Hon Ng,Fengcai Zhu,Ningshao Xia +23 more
TL;DR: Wang et al. as mentioned in this paper showed that vaccination with this hepatitis E vaccine induced antibodies against HEV and provided protection against hepatitis E for up to 4.5 years, while the rate of adverse events was similar in the two groups.
Journal ArticleDOI
Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.
Jun Zhang,Chong-bo Liu,Rong-Cheng Li,Yimin Li,Yingjie Zheng,Yan-ping Li,Dong Luo,Bai-bin Pan,Yi Nong,Shengxiang Ge,Junhui Xiong,James Wai-Kuo Shih,Mun-Hon Ng,Ningshao Xia +13 more
TL;DR: The results showed that the candidate recombinant hepatitis E vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection.
Journal ArticleDOI
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao,Ting Wu,Rong-Cheng Li,Yuemei Hu,Lihui Wei,Changgui Li,Wen Chen,Shoujie Huang,Fang-Hui Zhao,Mingqiang Li,Qin-Jing Pan,Xun Zhang,Qing Li,Ying Hong,Chao Zhao,Wen-hua Zhang,Yanping Li,Kai Chu,Mei Li,Yun-Fei Jiang,Juan Li,Hui Zhao,Zhijie Lin,Xuelian Cui,Wen-Yu Liu,Caihong Li,Dong-Ping Guo,Li-Dong Ke,Xin Wu,Jie Tang,Guo-Qi Gao,Ba-Yi Li,Bin Zhao,Fengxian Zheng,Cui-Hong Dai,Meng Guo,Jun Zhao,Yingying Su,Junzhi Wang,Fengcai Zhu,Shaowei Li,Huirong Pan,Yimin Li,Jun Zhang,Ningshao Xia +44 more
TL;DR: The Escherichia coli-produced HPV- 16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.